Insights Care: Chris Perkin — A Forward Thinker in the Research Space!
Five Lesser-Known Uses for PCR
PCR testing has been in the spotlight as the most reliable way of screening for COVID-19 in patients since the beginning of the pandemic. But what is PCR? And what are its other uses?
[Video] Ethnobridging Studies
Watch the Ethnobridging Webinar On‑Demand
Altasciences recently released a webinar on ethnobridging studies in which Dr. Affrime demonstrates how ethnobridging can help minimize time lags in development of drugs destined for Asian markets. Included are detailed case studies on how to include ethnobridging in your early clinical development plans to safely speed up worldwide regulatory approval.
To learn how Altasciences can assist you with your clinical research program, contact us today!
You may also be interested in the following webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Up Close and Personal With Marie-Hélène Raigneau, MBA, Co-Chief Operating Officer
Marie-Hélène has been a leader in the drug development industry for close to 20 years.
Checklist for a Successful First-In-Human Trial
Planning Your First In Human Trial
Check out this issue of The Altascientist for your roadmap to successfully conducting FIH studies, including:
- Determining the necessary regulatory interactions
- Selecting the starting dose
- Designing the trial
- Planning for participant safety
- Identifying and mitigating potential risks
- Recruiting, educating, and retaining study participants
- Planning resources and conducting the trial
You may also be interested in the following:
Webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Making Sense of Antisense Oligonucleotides (ASOs)
ASOs — The Importance of Sensitive Bioanalytical Assays
Precise quantitation of ASOs helps you target the source of a disease’s pathogenesis. Chemical modifications of ASOs and advancements in drug delivery have improved drug stability and potency, reducing the requirements for quantity of drug per dose, and total number of doses.
Altasciences has expertise in the development of highly sensitive bioanalytical assays for the quantitation of ASOs in complex biological matrices such as eye, liver, or brain tissue, adapted to the different critical parameters of your preclinical or clinical study:
- The ability to quantitate ASOs to very low concentrations impacts calculation of half-life; more sensitive assays will produce more accurate readouts.
- Timepoints close to the end of the dosing cycle are expected to have lower concentrations in various tissues. Highly sensitive methods will produce the most accurate readings, allowing for an accurate PK profile even in late timepoints.
- Hybridization-based methods provide the best reported assay sensitivity and throughput, compared with other bioanalytical methods for ASOs. They are less time consuming, requiring little or no sample clean-up, and have been widely used for the quantitative analysis of ASOs to support both TK and PK regulated bioanalysis.
Take a deeper dive into our ASO capabilities and knowledge, and consult our two case studies, in the 12th issue of The Altascientist.
Want more info?
- Webpage: Comprehensive Bioanalytical Services
- PDF: Altasciences' Proprietary Bioanalytical Assay List
- Podcast: Three Laboratories — One Vision
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Safety Pharmacology Case Studies, Webinar On-Demand
You Won’t Want to Miss This Video!
Watch as, Dr. Michael R. Gralinski, CEO of CorDynamics, reviews the results of three GLP safety pharmacology validation studies.
The studies were conducted using telemetered dogs with well-characterized hemodynamic, electrocardiographic, and respiratory positive controls. All three studies demonstrated the ability to detect expected effects of positive controls with a high degree of reliability.
The studies were conducted in Altasciences' purpose-built, isolated telemetry facility, with data review and interpretation by CorDynamics.
Speak with one of our experts today.
You may also be interested in:
• The Altascientist: Scientific Journal Issue 13 — Safety Pharmacology Studies, a Review
• Fact Sheet: Safety Pharmacology
• Webpage: Safety Pharmacology Overview and FAQs
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
Endpoints News: Canadian CRO Altasciences Kicks Off Client Manufacturing Expansion in Philadelphia
eBook – Monitoring Key Biomarkers of Immunomodulation
Altasciences has published a new eBook sharing comprehensive information about testing biomarkers of immunomodulation as part of your drug development program.
With the movement toward personalized treatments having immunomodulatory effects, monitoring complement factors and cytokines has become increasingly important to help prevent any unintended consequences that may arise from these new medications.
Contents include:
- REVIEW: Complement Factors and Cytokines
- SOLUTIONS: Biomarker Analysis
- CASE STUDY: Comparing Cytokine Data to In-Life Parameters on Nonhuman Primates in Nonclinical Toxicology Studies
- STUDY OUTLINE TEMPLATE: Nonclinical Study
Altasciences has been delivering excellence in bioanalytical services for over 25 years, and is fully equipped to analyze a comprehensive range of biomarkers to support your nonclinical toxicology programs. With over 260 scientists working in state-of-the-art laboratories and shifts running 24/7, as needed, our laboratory teams are able to process as many as 60,000 samples per month.
You may also be interested in the following:
- Poster: Multiplexed Cytokine Comparison Across Two Species Dosed With the Same Drug
- Poster: Evaluating Cytokine Data in Nonhuman Primate Safety Assessment Studies: A Correlation to Toxicity Outcomes
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.